{"id":"tgrx-678","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL5742056","moleculeType":null,"molecularWeight":"601.11"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TGRX-678 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly useful for the treatment of type 2 diabetes.","oneSentence":"TGRX-678 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:11.129Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07489755","phase":"PHASE3","title":"TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2026-04-01","conditions":"Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":180},{"nctId":"NCT06986772","phase":"PHASE1","title":"TGRX-678 Pharmacokinetic Mass Balance","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2025-07-07","conditions":"Chronic Myeloid Leukemia","enrollment":6},{"nctId":"NCT06697899","phase":"PHASE1","title":"TGRX-678 Phase I Oral Pharmacokinetic Study","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-11-24","conditions":"Chronic Myeloid Leukemia","enrollment":76},{"nctId":"NCT05434312","phase":"PHASE1","title":"TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2021-03-29","conditions":"Chronic Myelogenous Leukemia","enrollment":90},{"nctId":"NCT06088888","phase":"PHASE1","title":"TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia","status":"RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-07-02","conditions":"Chronic Myelogenous Leukemia","enrollment":90},{"nctId":"NCT06453902","phase":"PHASE2","title":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","status":"RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-07-15","conditions":"Chronic Myeloid Leukemia, Accelerated Phase CML","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TGRX-678","genericName":"TGRX-678","companyName":"Shenzhen TargetRx Co., Ltd.","companyId":"shenzhen-targetrx-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TGRX-678 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}